JAMA Therapeutics (JAMA Tx) is a preclinical-stage cardiac gene therapy spin-off from the Experimental Cardiology lab at the University Medical Center Utrecht in the Netherlands. Inherited cardiomyopathies affect roughly 1 in 200 to 500 people, yet care is still largely limited to symptom management or heart transplantation because disease-modifying cardiac gene therapy remains constrained by the safety and efficacy limits of today’s delivery vehicles in reaching the heart. JAMA Tx is developing two proprietary cell-derived nanoparticle delivery platforms designed to transport RNA, proteins, and programmable gene editors into hard-to-reach cells. Our approach combines biology-first delivery, endogenous cargo loading, and a platform strategy that supports multiple therapeutic programs. Through our proprietary delivery platform, we are advancing two cardiac gene therapy programs aimed at enabling durable, disease-modifying treatments for patients with life-threatening inherited heart disease.